PL2.2 Pembrolizumab (PEM) in recurrent high-grade glioma (HGG)patients with mismatch repair deficiency (dMMR): an observational study

BACKGROUND: Pem, an immune checkpoint inhibitor, demonstrated to be activein various neoplasms with MMRd. No data exists about its efficacy in MMRdglioma patients. MATERIAL AND METHODS: MMRd HGG relapsed after receiving RT and CT weretreated with Pem. MMR status was analyzed by immunohistochemistry,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Caccese, M, Simonelli, M, Fassan, M, Padovan, M, Persico, P, Bellu, L, Dipasquale, A, Gardiman, M, Indraccolo, S, Zagonel, V, Lombardi, G
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Oral Presentations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6794938/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz126.003
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados